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p21-Activated Kinase 4 Critically Regulates
Melanogenesis via Activation of the CREB/MITF
and b-Catenin/MITF Pathways
Cheong-Yong Yun1, Soon-Tae You1, Jin-Hwa Kim2, Jin H. Chung3, Sang-Bae Han4, Eun-Young Shin1 and
Eung-Gook Kim1
p21-activated kinase 4 (PAK4) regulates a wide range of cellular events, including cytoskeletal remodeling, cell
growth, and survival. Our previous study identified PAK4 as a key regulator of cAMP-response element–binding
protein (CREB) that acts upstream of microphthalmia-associated transcription factor (MITF), a master transcription
factor in melanogenesis. We therefore investigated the role of PAK4 in melanogenesis. Melanocytes express both
PAK2 and PAK4 isoforms, but only RNA interference knockdown of PAK4 significantly influenced a-melanocyte-
stimulating hormone (a-MSH)–induced melanogenesis in B16 melanoma cells. Consistent with this result, PAK4
inhibition by PF3758309, a potent ATP-competitive inhibitor of PAKs, suppressed not only a-MSH–induced
melanogenesis in B16 melanoma and human epithelial melanocyte cells but also UVB-induced melanogenesis in
the skin of melanin-possessing hairless mice (HRM-2) in a dose-dependent manner. Inhibition of PAK4 over several
days markedly decreased the levels of CREB, MITF, and tyrosinase in both HRM-2 mice and B16 melanoma cells.
Moreover, PAK4 knockdown and inhibition suppressed a-MSH-stimulated b-catenin phosphorylation at serine 675
(S675) but enhanced phosphorylation at S33/37, an indicator for ubiquitination-dependent proteolysis. Together,
our results provide evidence that PAK4 promotes a-MSH/UVB-induced melanogenesis via the CREB and Wnt/b-
catenin signaling pathways and suggest that PAK4 may be a potential therapeutic target in pigmentation disorders.
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INTRODUCTION
p21-activated kinase (PAK) is a key regulator of diverse
cellular processes. PAKs can be divided into two groups:
group I (PAK1–3) and group II (PAK4–6) (Arias-Romero and
Chernoff, 2008). PAK4 has an important role in the
reorganization of actin cytoskeleton and thus influences cell
shape and motility (Abo et al., 1998). PAK4 has been shown to
mediate the anti-apoptotic effect of keratinocyte growth factor
(Lu et al., 2003). PAK4 directly binds the keratinocyte growth
factor receptor, and this association mediates the protection of
lung epithelial cells from oxidant stress. PAK4 is upregulated
during the differentiation of epidermal keratinocytes and has
been suggested to protect these cells (Lu et al., 2003).
However, the functional role for PAK4 in melanocytes in
melanogenesis remains unknown.
Melanin pigment is synthesized in melanocytes and trans-
located to keratinocytes, protecting the skin from hazardous
environmental stimuli such as UV radiation. The solar UV
spectrum can be divided into three groups according to
wavelength: UVA (320–400 nm), UVB (280–320 nm), and
UVC (200–280 nm). Among these UV wavelengths, UVB has
melanogenic properties (Maeda and Hatao, 2004; Wolber
et al., 2008; Choi et al., 2010; Miyamura et al., 2011). UVB
radiation induces melanogenesis through a complex process
that requires interplay between keratinocytes and melanocytes
(Cui et al., 2007; Lin and Fisher, 2007; Yamaguchi and
Hearing, 2009) or directly through p38 MAPK–dependent
phosphorylation of cAMP-response element (CRE)-binding
protein (CREB) at serine 133 (S133) (Saha et al., 2006),
which enhances the expression of microphthalmia-asso-
ciated transcription factor (MITF), the master regulator of
melanogenesis. Upon exposure to UVB, keratinocytes
secrete paracrine factors that promote melanin synthesis in
melanocytes. Among these secreted factors, a-melanocyte-
stimulating hormone (a-MSH) is a key agonist in stimulating
melanogenesis. The signaling pathway for a-MSH-induced
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melanogenesis has been intensively investigated and found to
primarily involve the cAMP/PKA pathway (Kreiner et al.,
1973; Wong and Pawelek, 1973; Ao et al., 1998). a-MSH
elevates cellular cAMP levels, which sequentially dissociates
the catalytic subunit from the regulatory subunit of PKA. The
free catalytic subunit of PKA then translocates to the nucleus
and phosphorylates CREB at S133 (Gonzalez and Montminy,
1989). The phosphorylated active form of CREB binds
and activates MITF (Bertolotto et al., 1998; Price et al.,
1998), which in turn stimulates the transcription of the key
melanogenic enzymes, such as tyrosinase, tyrosinase-related
protein-1, and tyrosinase-related protein-2. MITF has a central
role in a-MSH-induced melanogenesis, and its expression and
activation are regulated in a complex manner. In addition
to CREB, lymphoid-enhancing factor-1, PAX3, and SOX10
cooperate to regulate MITF expression in a transcription-
dependent manner (Watanabe et al., 1998; Bondurand
et al., 2000; Lee et al., 2000; Potterf et al., 2000; Takeda
et al., 2000; Verastegui et al., 2000).
Wnt/b-catenin signaling contributes to melanogenesis by
inducing the formation of a MITF/b-catenin/lymphoid-enhan-
cing factor-1 complex that binds to the tyrosinase promoter,
which in turn upregulates tyrosinase (Schepsky et al., 2006).
This regulatory mechanism requires the stabilization of
b-catenin, which can be achieved by PKA-dependent phos-
phorylation of b-catenin at S675 (Hino et al., 2005; Bellei
et al., 2011). Moreover, Li et al. (2012) demonstrated that the
S675 residue of b-catenin is also a target of PAK4, indicating
the involvement of PAK4 in melanogenesis.
Our recent study implicated PAK4 as a critical regulator of
CREB (Park et al., 2013) that elevates MITF transcription in
UV/a-MSH-induced melanogenesis. We therefore hypothesized
that PAK4 mediates melanogenesis by regulating CREB and
b-catenin/lymphoid-enhancing factor-1. We found that PAK4
inhibition suppressed melanogenesis in a dose-dependent
manner in vivo and in vitro. The underlying mechanism for
PAK4-mediated melanogenesis involves activation of the CREB/
MITF/tyrosinase and b-catenin/MITF/tyrosinase pathways.
RESULTS
Epidermal melanocytes and B16 melanoma cells express both
PAK2 and PAK4
To investigate the role of PAK in melanogenesis, we first
determined which PAK isoform is expressed in B16 melanoma
cells and the epidermis of HRM-2 mice. Using SOX10 as a
melanocyte marker (Nonaka et al., 2008; Shin et al., 2012),
we performed immunohistochemistry to identify which PAK
isoform colocalizes with SOX10 in the epidermis of HRM-2
mice. As illustrated in Figure 1a, PAK2 and PAK4 but not other
PAK isoforms stained in the epidermis. Moreover, PAK2 and
PAK4 co-stained with SOX10, suggesting their specific func-
tions in melanocytes. We further examined the expression of
PAK isoforms in B16 melanoma cells, which have been
widely used as a melanogenesis model. Consistent with the
in vivo results, immunoblotting revealed only PAK2 and PAK4
expression in B16 melanoma cells (Figure 1b). Exogenous
PAK4 appeared larger compared with the endogenous form
because of the addition of a 3 Myc tag.
PAK4 mediates a-MSH-stimulated melanogenesis in vitro
To determine which PAK isoform contributes to melanogen-
esis, we first examined whether PAK2 is activated in response
to a-MSH. In its activation process, PAK2 is phosphorylated at
threonine 402. Thus, activated PAK2 can be detected by an
antibody that recognizes this phosphorylated form of PAK2.
a-MSH stimulated PAK2 activation in a time- and concentra-
tion-dependent manner (Supplementary Figure S1a online).
Because PAK2 responded to a-MSH stimulation, we next
examined the effect of PAK2 knockdown on a-MSH-induced
melanogenesis. To deplete cellular PAK2, two different PAK2-
specific small interfering RNAs (siRNAs) were used that
markedly decreased PAK2 levels to a similar extent
(Supplementary Figure S1b online, right). However, a-MSH
strongly induced melanin synthesis in PAK2 siRNA-treated
cells and scrambled siRNA-treated cells (Supplementary
Figure S1b online, left). Arbutin is a specific inhibitor of
tyrosinase, which catalyzes melanin synthesis (Akiu et al.,
1991). Thus, it has been widely used as a melanogenesis
inhibitor. As expected, arbutin inhibited a-MSH-induced
melanogenesis in a concentration-dependent manner.
Because the above results suggested that PAK4 mediates
melanogenesis, we next examined whether a-MSH stimulates
PAK4 activation. PAK4 activation was indirectly monitored
by measuring phosphorylation at serine 474 (pPAK4S474,
hereafter referred to as pPAK4; Callow et al., 2002). a-MSH
increased pPAK4 levels in a concentration-dependent manner
up to 100 nM (Figure 2a). However, this phosphorylation was
markedly suppressed by pre-incubation with the PKA inhibitor
H89, which did not directly inhibit PAK4 (Supplementary
Figure S2a online). These results indicate that PAK4 partially
functions downstream of PKA. PAK4 phosphorylation began
5 minutes after a-MSH stimulation, reached a plateau at
15–30 minutes, and gradually decreased to basal levels at
60 minutes (Figure 2b). We then applied PF3758309, which
was initially discovered as a PAK4-specific inhibitor (Murray
et al., 2010), but was then found to have inhibitory activity
toward all PAK isoforms. PF3758309 suppressed a-MSH-
stimulated PAK4 phosphorylation in a concentration-
dependent manner in B16 melanoma and human epithelial
melanocyte (HEM) cells (Figure 2c). PF3758309 did not
directly inhibit PKA, which excludes the possibility that its
inhibitory effect was due to inhibition of an upstream PKA
(Supplementary Figure S2b online). PF3758309 alone at the
maximum concentration did not induce significant cytotoxi-
city (Supplementary Figure S3 online). Furthermore, we
performed immunocytochemistry for pPAK4 in B16 melanoma
cells. pPAK4 reactivity increased approximately B5-fold,
mostly in the nucleus, compared with unstimulated controls
(Figure 2d). With increasing concentrations of PF3758309,
pPAK4 nuclear staining gradually declined. We next examined
whether PAK4 is essential for a-MSH-induced melanogenesis
in B16 melanoma cells (Figure 2e, left). Melanin content was
measured three days after stimulation with a-MSH, and
PF3758309 was found to decrease the a-MSH-stimulated
synthesis of melanin pigment in a concentration-dependent
manner with an IC50 value of 38 nM. Arbutin had an IC50
value of 78mM; thus, the inhibitory potency of PF3758309
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Figure 1. Expression of p21-activated kinase (PAK) isoforms in the skin and B16 melanoma cells. (a) The skin of HRM-2 mice was co-stained for PAK1, 2, 4, or 6
(green) with SOX10, a melanocyte marker (red). Immunostaining for the pairs PAK3/SOX10 and PAK5/SOX10 was performed using two adjacent slides. White
arrows indicate SOX10-positive cells. The nucleus was then stained with 4’,6-diamidino-2-phenylindole (DAPI) (blue). Scale bar¼ 5mm. (b) Immunoblotting was
performed to detect the expression of PAK isoforms in B16 melanoma cells. Each exogenous PAK isoform in a myc-tagged form was transfected as a positive
control.
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Figure 2. p21-activated kinase-4 (PAK4) inhibition and knockdown suppress a-melanocyte-stimulating hormone (a-MSH)-stimulated melanogenesis.
(a and b) a-MSH stimulated PAK4 phosphorylation concentration (a) and time (b) dependently. (c and d) Cells were pretreated with PF3758309 4 hours before
stimulation with a-MSH for 15 minutes and subjected to immunoblotting (c) and immunofluorescence measurement (d, left). Scale bar¼ 10mm. pPAK4 fluorescence
intensity was quantified (d, right). (e) Cells were treated with PF3758309 for the first day and stimulated with a-MSH for 3 days. Melanin content was quantified.
Values indicate the mean±SE from three independent experiments. *Po0.01. (f) Left, small interfering RNA (siRNA)-transfected cells were stimulated with a-MSH for
3 days, and melanin content was measured. Values are from three independent experiments. *Po0.01. Right, PAK4 knockdown was monitored by immunoblotting.
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was B2,000-fold greater than that of arbutin. PF3758309
induced a similar concentration-dependent decrease in both
PAK4 phosphorylation and melanogenesis in HEM cells
(Figure 2e, right). Next, we performed PAK4 knockdown.
PAK4-specific siRNAs markedly decreased CREB and endo-
genous PAK4 levels (Supplementary Figure S4 online), which
is consistent with the results of a previous study (Park et al.,
2013). The expression of siRNA-resistant forms of human
PAK4 restored the CREB levels, indicating no substantial
off-target effects. Knocking down PAK4 with these siRNAs
suppressed a-MSH-stimulated melanogenesis to basal levels
(Figure 2f). These results strongly suggest that PAK4 is critically
required for a-MSH-stimulated melanogenesis.
PAK4 mediates UVB-induced melanogenesis in vivo
UVB-induced melanogenesis involves a-MSH, which is
secreted from keratinocytes upon exposure to UVB (Dong
et al., 2010). We investigated whether PAK4 has a similar role
in UVB-induced melanogenesis in vivo. For this study, we
used HRM-2 mice, which are hairless but have the capacity to
synthesize melanin pigments. PF3758309 was delivered to the
skin of HRM-2 mice as a cream mixture to inhibit PAK4. As
shown in Figure 3a, HRM-2 mice were exposed to UVB
radiation at increasing intensities. To reduce errors from
mouse-to-mouse variations in pigmentation intensity, the back
of each mouse was divided into three parts (Figure 3b). We
first investigated whether PAK4 is activated in epidermal
melanocytes in response to UVB radiation. To this end, we
performed co-staining of pPAK4 with SOX10 and quantified
pPAK4 levels in SOX10-positive cells. UVB radiation strongly
elevated pPAK4 levels (Figure 3c). Pretreatment with
PF3758309 decreased the intensity of pPAK4 in a dose-
dependent manner (Figure 3c; quantified in Figure 3d).
PF3758309 alone at the maximum concentration of 10mM
did not induce apoptosis in the epidermis of HRM-2 mice
(Supplementary Figure S5 online), indicating that UVB radia-
tion stimulated PAK4 activation in epidermal melanocytes.
Next, we examined the effect of PF3758309 on UVB-stimu-
lated melanogenesis. UVB-irradiated skin did not exhibit
significant changes in pigmentation until day 6, as quantified
by the L values, which were inversely correlated with the
degree of skin pigmentation (Figure 3e). Further repeated
exposure to UVB increased pigmentation, which peaked on
day 14, as indicated by the lowest L value of 59 (Figure 3e).
PAK4 inhibition by PF3758309 attenuated the UVB-induced
increase in skin pigmentation in a dose-dependent manner
(Figure 3e and Supplementary Figure S6a online). The inhibi-
tory effect of PF3758309 at 2mM was comparable to that of
arbutin at 2 mM. Consistent with the skin pigmentation results,
UVB-induced melanin synthesis was suppressed by
PF3758309 (Supplementary Figure S6b online). Together, the
results suggest that PAK4 mediates UVB-induced melanogen-
esis in vivo.
PAK4 mediates melanogenesis by upregulating CREB/MITF/
tyrosinase
To identify the molecular mechanisms by which PAK4 mediates
melanogenesis, we determined whether PAK4 knockdown or
inhibition influences the levels of pCREB, CREB, MITF, and
tyrosinase, the key signaling molecules involved in melano-
genesis. CREB binds and activates the MITF promoter, which
in turn stimulates the transcription of tyrosinase (Saito et al.,
2003; Widlund and Fisher, 2003). We first examined the effect
of PAK4 knockdown. As illustrated in Figure 4a, PAK4
knockdown in B16 melanoma and HEM cells nearly depleted
pCREB, CREB, MITF, and tyrosinase. To further analyze CREB
binding to the MITF promoter, we performed a reporter assay
for MITF promoter activity. a-MSH stimulated the reporter
activity of the MITF promoter B2.8-fold compared with that
in untreated control cells, whereas PAK4 silencing negated
this stimulation (Figure 4b). Together with PAK4 knockdown–
induced abrogation of CREB and pCREB (Figure 4a), these
results suggest that PAK4 regulates the MITF promoter activity
through CREB. In support of this suggestion, PAK4 knockdown
also markedly downregulated tyrosinase, a downstream target
of MITF (Figure 4a). We next examined the effect of PAK4
inhibition. Short-term treatment with PF3758309 did not affect
CREB protein levels (data not shown). B16 melanoma cells
were thus treated for 22 hours before stimulation with a-MSH
for 15 minutes (Figure 4c). As shown by immunoblotting,
CREB, MITF, and tyrosinase levels were decreased by treat-
ment with 100 and 300 nM PF3758309 (Figure 4d and e).
pCREB levels were affected only by 300 nM PF3758309,
suggesting that the decreased levels may result from down-
regulation rather than a direct effect on its phosphorylation.
The specific PKA inhibitor H89 nearly completely blocked the
phosphorylation of CREB at serine 133 (Figure 4d), suggesting
that PAK4 knockdown or inhibition of expression may prevent
a-MSH-stimulated melanogenesis in B16 melanoma cells by
downregulating CREB, MITF, and tyrosinase. To confirm the
inhibitory effect on UVB-induced melanogenesis in vivo, we
performed immunohistochemistry with SOX10 in the epider-
mis, which was prepared as described above in Figure 3c.
Thus, we quantified CREB, MITF, and tyrosinase levels in
SOX10-positive cells (Figure 4f, white arrows). CREB was
localized to the melanocyte nuclei, and basal CREB levels
were significantly higher before UVB exposure. Accordingly,
UVB radiation did not substantially upregulate CREB, but
PAK4 inhibition decreased CREB levels in a concentration-
dependent manner (Figure 4f, left; Supplementary Figure S7
online). In contrast to CREB, expression of MITF and tyrosinase
was strongly induced by UVB exposure. PAK4 inhibition also
decreased the UVB-induced upregulation of MITF and tyrosi-
nase in a concentration-dependent manner (Figure 4f, middle
and right; Supplementary Figure S8 and S9 online).
PAK4 mediates melanogenesis via b-catenin activation
b-catenin contributes to melanogenesis by interacting with
MITF, which elevates the transcription of the tyrosinase gene
(Schepsky et al., 2006). In addition, a-MSH has been reported
to stimulate Wnt/b-catenin signaling (Bellei et al., 2011).
Recent studies have shown that PAK4 directly enhances b-
catenin phosphorylation at serine 675 (pb-cateninS675), which
leads to b-catenin stabilization by inhibiting its degradation
(Hino et al., 2005). We therefore examined the effect of PAK4
inhibition on b-catenin phosphorylation. a-MSH stimulated
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b-catenin phosphorylation at S675 in a concentration- and
time-dependent manner in B16 melanoma cells (Figure 5a).
PAK4 inhibition blocked a-MSH-stimulated b-catenin phos-
phorylation at S675 in a concentration-dependent manner in
B16 melanoma cells (Figure 5b, top). Further, PAK4 knock-
down significantly suppressed a-MSH-stimulated b-catenin
phosphorylation at S675 (Figure 5b, bottom). We next exam-
ined the effect of PAK4 inhibition in vivo. We performed
immunohistochemistry for pb-cateninS675 and SOX10 in the
epidermis of UVB-irradiated HRM-2 mice (Figure 5c). pb-
cateninS675 was primarily stained in the cell membrane
(Figure 5c, second column). The intensity of pb-cateninS675
staining gradually decreased with increasing concentrations of
PF3758309. b-catenin is also subject to ubiquitination-depen-
dent proteolysis when phosphorylated at S33/37 (pb-cate-
ninS33/37) (Liu et al., 2002). We therefore investigated whether
PAK4 inhibits phosphorylation at these residues. Pretreatment
with cyclohexamide and MG132, a proteasome inhibitor,
markedly increased pb-cateninS33/37 levels (Figure 5d, com-
pare lanes 1 and 2). Stimulation with a-MSH substantially
decreased pb-cateninS33/37 levels in control siRNA-treated
cells (lane 3) but not in PAK4 knockdown B16 melanoma
and HEM cells (lanes 4 and 5). PF3758309 also inhibited
the a-MSH-induced decrease in pb-cateninS33/37 levels
(Figure 5e). We confirmed that this effect was not due to
direct inhibition by PF3758309 of GSK3b, which phosphor-
ylates b-catenin at S33/37 (Supplementary Figure S2c online).
Therefore, PAK4 may stabilize b-catenin by a dual mechanism
in which PAK4 enhances b-catenin phosphorylation at S675
but blocks b-catenin phosphorylation at S33/37.
DISCUSSION
In the present study, we demonstrated that PAK4 has a key
role in a-MSH/UV radiation–induced melanogenesis. PAK4
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activation promoted melanogenesis by functioning upstream
of two key transcription factors––CREB and b-catenin (Figure 6).
PAK4 knockdown and inhibition downregulated CREB.
Because expression of MITF and tyrosinase is tightly controlled
by CREB, CREB downregulation sequentially decreased MITF
and tyrosinase levels, which ultimately led to a decrease in
melanin synthesis. PAK4 inhibition suppressed a-MSH/UV
radiation–stimulated phosphorylation of b-catenin at S675.
Therefore, activated PAK4 facilitates melanogenesis via two
distinct signaling pathways: the CREB/MITF/tyrosinase and
b-catenin/MITF signaling pathways.
In contrast to b-catenin, it remains unclear how activated
PAK4 maintains CREB stability. CREB is subject to ubiquitina-
tion-dependent degradation in hypoxia (Taylor et al., 2000).
However, the kinase responsible for targeting CREB to the
ubiquitination-dependent proteolysis has not yet been defined.
Additional studies are required to delineate the molecular
mechanism by which PAK4 sustains CREB levels. PAK4
appears to mediate melanogenesis by preventing the
degradation of the key molecules in melanogenesis, such as
CREB and b-catenin. Thus, PAK4 knockdown or inhibition
could be an intervening approach to hyperpigmentation
disorders and skin whitening.
Accumulated evidence indicates that PAKs, particularly the
PAK1 and PAK4 isoforms, have a vital role in tumorigenesis
and tumor progression. Therefore, the development of PAK
isoform–specific inhibitors has long been the subject of intense
study. Notably, PF3758309 was initially developed as an anti-
cancer drug targeting PAK4, but it is currently recognized as a
pan-PAK inhibitor. Because of the lack of a PAK4-specific
inhibitor, we used PF3758309 to examine the effect of PAK4
on melanogenesis in the epidermis. Immunofluorescence ana-
lysis revealed expression of both PAK2 and PAK4 in epidermal
melanocytes. Adding to the complexity, their activity increased
in response to a-MSH in a time- and concentration-dependent
manner (Supplementary Figure S1a online and Figure 2).
Although we excluded a role for PAK2 in a-MSH-induced
melanogenesis in B16 melanoma cells (Supplementary Figure
S1b online), PAK2 still may be involved in UV radiation–
induced melanin synthesis in the epidermis. Thus, the effect of
PF3758309 on UV-induced skin pigmentation may be partially
mediated by PAK2 inhibition, which warrants the future
development of PAK isoform–specific inhibitors.
The present study focused on the role of PAK4 in melano-
genesis; however, PAK4 may have additional roles in the
epidermis, as evidenced by the diverse cellular functions of its
downstream targets––CREB, MITF, and b-catenin. When
introduced into melanoma cells, dominant-negative CREB,
which can form a heterodimer but has poor DNA-binding
affinity, inhibited tumor growth and metastasis and rendered
the cells susceptible to radiation-induced apoptosis (Xie et al.,
1997). Approximately half of all melanoma patients display
constitutively activated mutant forms of BRAF kinase.
Recent studies have revealed a crucial role for MITF in vivo
as a downstream target of BRAFV600E, the major form of
BRAF mutation, in melanoma development (Wellbrock et al.,
2008). PAK4 knockdown in cancer cells harboring BRAF
mutations resulted in a B50% decrease in proliferation
(Tabusa et al., 2013). In light of these findings, it would be
interesting to investigate whether PAK4 links BRAF and MITF
in melanoma formation. b-catenin directly activates MITF
transcription; thus, its stabilization enhances BRAFV600E-driven
melanoma formation (Damsky et al., 2011). Therefore,
repeated exposure to sunlight over certain thresholds may
lead to the development and progression of skin tumors by
activating PAK4/CREB and/or PAK4/b-catenin signaling
that converges on MITF. Considering this role for PAK4 in
melanoma, PAK4 inhibition may also help prevent photo-
carcinogenesis and hyperpigmentation caused by aberrant
melanogenesis.
MATERIALS AND METHODS
Materials
Primary antibodies were purchased from Cell Signaling Technology
(Danver, MA, USA), Santa Cruz Biotechnology (Santa Cruz, CA,
USA), or Abcam (Cambridge, UK). Horseradish peroxidase-conju-
gated secondary antibodies were purchased from Thermo Scientific
(Middletown, VA, USA). Biotinylated secondary antibodies, the
VECTASTAIN ABC system, and the Vectashield mounting medium
were purchased from Vector Laboratories (Burlingame, CA, USA).
PF3758309 and other chemicals were purchased from Sigma-Aldrich
(St Louis, MO, USA). PAK4-specific siRNAs, no. 1404672 and no.
MSS291252, were purchased from Bioneer and Life Technologies,
respectively. HRM-2 mice were purchased from Hoshino Laboratory
Animals (Yashino, Saitama, Japan). Animal experiments were per-
formed in accordance with the approved animal protocols and the
guidelines established by the Ethics Review Committee of Chungbuk
National University for Animal Experiments (CBNUA-488-12-01).
Cell culture
B16 melanoma cells were cultured in DMEM supplemented with
10% fetal bovine serum, and HEM cells were grown in medium 254
supplemented with HMGS at 37 1C under a humidified incubator
containing 5% CO2.
Figure 4. p21-activated kinase-4 (PAK4) knockdown and inhibition downregulate pCREB, cAMP-response element–binding protein (CREB), microphthalmia-
associated transcription factor (MITF), and tyrosinase. (a) B16 melanoma (left) and human epithelial melanocyte (HEM; right) cells were transfected with small
interfering RNAs (siRNAs) for 3 days and then stimulated with a-melanocyte-stimulating hormone (a-MSH). Immunoblotting was performed. (b) B16 melanoma
cells were transfected with siRNAs, MITF-luc reporter, and Renilla plasmids. Cells were treated with H89 for 2 hours before stimulation with a-MSH for 4 hours.
Reporter assay was performed. *Po0.01. (c) Experimental design. Cells were pretreated with PF3758309 for 22 hours and harvested depending on the activation or
expression time of the indicated proteins after a-MSH stimulation. (d and e) PF3758309-pretreated cells were harvested at 15 minutes for pCREB and CREB, 4 hours
for MITF, and 2 days for tyrosinase after a-MSH stimulation, respectively, and immunoblotted. (f) Top, HRM-2 skin was processed as described in Figure 3,
followed by immunohistochemical staining for CREB, MITF, and tyrosinase (green) and SOX10 (red). White arrows, SOX10-positive cells; yellow arrows, double-
positive cells. Scale bar¼10mm. Bottom, CREB-, MITF-, and tyrosinase-stained cells in SOX10-positive cells were quantified (n¼ 60). *Po0.01.
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Transient transfection with siRNA or DNA
Cells were transfected using Lipofectamine 2000 reagent according to
the manufacturer’s instructions. Briefly, 100 nM siRNA or 5mg of DNA
was diluted with 5ml of Lipofectamine 2000 in OPTI-MEM and added
to the cells. After 2 or 3 days, the transfected cells were harvested for
further experiments.
Melanin content assay
B16 melanoma cells or melanocytes were stimulated with
a-MSH (100 nM) for 3 days. Cells were counted and lysed with
1 M NaOH and 20% DMSO at 70 1C. The absorbance was
measured at 405 nm using a SpectraMax M5 reader (Molecular
Devices, Sunnyvale, CA, USA) and normalized to the cell number.
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Figure 5. p21-activated kinase-4 (PAK4)-b-catenin signaling in a-melanocyte-stimulating hormone (a-MSH)-stimulated melanogenesis. (a) Cells were treated with
a-MSH with the indicated doses (top) and for the indicated times (bottom) and then subjected to immunoblotting. (b) Top, cells were pretreated with PF3758309 for
6 hours before stimulation with a-MSH for 15minutes, followed by immunoblotting. Bottom, cells were transfected with small interfering RNAs (siRNAs) for 3 days
and then stimulated with a-MSH. (c) Top, cells were immunostained for pb-cateninS675 (green) and SOX10 (red). Scale bar¼10mm. Bottom, pb-catenin S675 in
SOX10-positive cells was quantified. *Po0.01. (d) Two days after transfection with siRNAs, B16 melanoma (left) and human epithelial melanocyte (HEM; right) cells
were treated with MG132 and cycloheximide for 2 hours and then stimulated with a-MSH for 90minutes. Immunoblotting was performed. (e) Cells were sequentially
treated with PF3758309 for 6 hours and MG132 and cycloheximide for 2 hours and stimulated with a-MSH for 90 minutes. Immunoblotting was performed.
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Measurement of skin pigmentation
Six-week-old HRM-2 mice were housed in a temperature-controlled
room (23±3 1C) with a relative humidity of 55±5% and a 12-hour
light/dark cycle. After a 2-week acclimation period, the mice were divi-
ded into four groups (n¼ 5 for each group) treated with 0.4, 2, or 10mM
PF3758309 or 2mM arbutin. The cream was applied to a designated site
(2 cm 2 cm) on the dorsal skin of HRM-2 mice before UVB radiation
with 100–200 mJ cm 2 using a UV cross-linker (UVP, Upland, CA,
USA). Skin color was measured using a CR-200B Handheld Chroma
Meter (Konica Minolta Sensing, Sakai, Osaka, Japan).
Immunocytochemistry and immunohistochemistry
Slides were sequentially incubated with blocking buffer (1% BSA, 0.1%
cold fish gelatin, 0.3% Triton X-100, 0.05% Tween 20, and 0.05%
sodium azide in phosphate-buffered saline (PBS)) for 1 hour at room
temperature and primary antibody at 4 1C overnight. After washing
with PBS-T, the slides were incubated in AlexaFluor 488– or 594–
conjugated secondary antibody for 1 hour in a dark chamber at room
temperature. After washing again with PBS-T, the slides were mounted
with Vectashield mounting medium. Images were photographed using
an Olympus fluorescence microscope (Olympus Optical, Tokyo,
Japan) equipped with a cooled CCD camera. Image processing and
data analysis were conducted using the ImageJ software.
For 3, 3 diaminobenzidine staining, the slides were treated with 3%
H2O2 to block endogenous peroxidase for 10 minutes, and the same
procedure was applied as described above except for a final step that
used 3, 3 diaminobenzidine solution (0.5 mg ml 1 DAB in 0.1 M
phosphate buffer, pH 7.4, with 0.003% H2O2) for visualization. After
sufficient washing with PBS, the slides were counterstained with
hematoxylin, dehydrated, and mounted with coverslip.
Statistical analysis
The data are expressed as the mean±SE. Statistical significance
was assessed by Student’s t-test using the SigmaPlot 10.0 software
(Systat Software, San Jose, CA). Po0.05 was considered significantly
different.
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